A case series of BRAF V600E inhibitor (PLX4032) related cutaneous eruptions in metastatic melanoma

被引：0
|
作者：
Sinha, R. [1 ]
Fearfield, L. [2 ]
Larkin, J. [1 ]
机构：
[1] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2011年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [41] Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
    Zhang H.
    Chen D.
    Thyroid Research, 11 (1)
  • [42] Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (07): : 234 - 235
  • [43] Vemurafenib in Melanoma with BRAF V600E Mutation REPLY
    Chapman, Paul B.
    Hauschild, Axel
    McArthur, Grant A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15): : 1450 - 1450
  • [44] Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032
    Chapman, P.
    Puzanov, I.
    Sosman, J.
    Kim, K.
    Ribas, A.
    McArthur, G.
    Lee, R.
    Grippo, J.
    Nolop, K.
    Flaherty, K.
    EJC SUPPLEMENTS, 2009, 7 (03): : 5 - 5
  • [45] BRAF V600E and V600K in Melanoma: Clinicopathologic Correlation
    Purgina, B. M.
    Jelic, T.
    Chiosea, S. I.
    LABORATORY INVESTIGATION, 2012, 92 : 131A - 131A
  • [46] BRAF V600E and V600K in Melanoma: Clinicopathologic Correlation
    Purgina, B. M.
    Jelic, T.
    Chiosea, S. I.
    MODERN PATHOLOGY, 2012, 25 : 131A - 131A
  • [47] BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
    Meevassana, Jiraroch
    Anothaisatapon, Kullawit
    Subbalekha, Surawish
    Kamolratanakul, Supitcha
    Siritientong, Tippawari
    Ruangritchankul, Komkrit
    Pungrasami, Pornthep
    Hamill, Kevin J.
    Angsapatt, Apichai
    Kitkumthorn, Nakarin
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2022, 10 (10) : E4605
  • [48] The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases The implications for BRAF inhibitor therapy
    Hannan, Enda J.
    O'Leary, Donal P.
    MacNally, Stephen P.
    Kay, Elaine W.
    Farrell, Michael A.
    Morris, Patrick G.
    Power, Colm P.
    Hill, Arnold D. K.
    MEDICINE, 2017, 96 (48)
  • [49] A Case of BRAF V600E Intrahepatic Cholangiocarcinoma
    Ahmed, Zarir
    Doane, Elizabeth
    Antao, Nirav
    Chhaparia, Anuj
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S1314 - S1315
  • [50] A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?
    Lade-Keller, Johanne
    Kristensen, Lasse Sommer
    Riber-Hansen, Rikke
    Guldberg, Per
    Hansen, Lise Lotte
    Steiniche, Torben
    Hager, Henrik
    JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (08) : 723 - 725
12345